Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

April 15, 2008 (Vol. 28, No. 8)

Emerging Firms Highlighted at Roth Meeting

Cancer Therapeutics Are a Mainstay of Businesses Whether Large or Small

  • T-cell therapy, oxidative stress, lipidomics, and parthenogenesis were some of the concepts discussed at the “20th Annual OC Growth Stock Conference” presented by Roth Capital Partners recently. Therapeutic antibody sales have increased significantly over the last decade. The market is currently pegged at $30 billion per year with $25 ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.